$RGEN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REPLIGEN CORP.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in REPLIGEN CORP. Get notifications about new insider transactions in REPLIGEN CORP for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 14 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Option Exercise | M | 86.10 | 1,045 | 89,975 | 2,092 | |
Jun 14 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Option Exercise | M | 59.52 | 2,557 | 152,193 | 1,354 | |
Jun 14 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 189.19 | 6,802 | 1,286,870 | 21,355 | 28.2 K to 21.4 K (-24.16 %) |
Jun 14 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Buy | M | 86.10 | 1,045 | 89,975 | 28,157 | 27.1 K to 28.2 K (+3.85 %) |
Jun 14 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Buy | M | 59.52 | 2,557 | 152,193 | 27,112 | 24.6 K to 27.1 K (+10.41 %) |
May 18 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 172.60 | 470 | 81,122 | 31,893 | 32.4 K to 31.9 K (-1.45 %) |
May 13 2021 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Option Exercise | M | 3.22 | 15,000 | 48,300 | 0 | |
May 13 2021 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 176.85 | 285 | 50,402 | 115,449 | 115.7 K to 115.4 K (-0.25 %) |
May 13 2021 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Buy | M | 3.22 | 15,000 | 48,300 | 115,734 | 100.7 K to 115.7 K (+14.89 %) |
Apr 08 2021 | RGEN | REPLIGEN CORP | Bylund James | SVP, Global Operati ... | Sell | S | 204.25 | 360 | 73,530 | 6,324 | 6.7 K to 6.3 K (-5.39 %) |
Mar 18 2021 | RGEN | REPLIGEN CORP | Gebski Christine | See Remarks | Sell | S | 196.88 | 1,400 | 275,632 | 37,140 | 38.5 K to 37.1 K (-3.63 %) |
Mar 16 2021 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Gift | G | 0.00 | 170 | 0 | 1,294 | 1.5 K to 1.3 K (-11.61 %) |
Mar 12 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 194.08 | 235 | 45,609 | 212,762 | 213 K to 212.8 K (-0.11 %) |
Mar 12 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 193.30 | 227 | 43,879 | 212,997 | 213.2 K to 213 K (-0.11 %) |
Mar 12 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 192.17 | 1,378 | 264,810 | 213,224 | 214.6 K to 213.2 K (-0.64 %) |
Mar 12 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 191.19 | 1,081 | 206,676 | 214,602 | 215.7 K to 214.6 K (-0.50 %) |
Mar 12 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 190.17 | 4,096 | 778,936 | 215,683 | 219.8 K to 215.7 K (-1.86 %) |
Mar 12 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 188.77 | 1,171 | 221,050 | 219,779 | 221 K to 219.8 K (-0.53 %) |
Mar 12 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 188.06 | 914 | 171,887 | 220,950 | 221.9 K to 221 K (-0.41 %) |
Mar 12 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Option Exercise | M | 59.52 | 150 | 8,928 | 3,911 | |
Mar 12 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Option Exercise | M | 33.87 | 5,850 | 198,140 | 0 | |
Mar 12 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Option Exercise | M | 33.05 | 2,000 | 66,100 | 2,000 | |
Mar 12 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 192.13 | 1,004 | 192,899 | 25,265 | 26.3 K to 25.3 K (-3.82 %) |
Mar 12 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 191.33 | 642 | 122,834 | 26,269 | 26.9 K to 26.3 K (-2.39 %) |
Mar 12 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 190.08 | 6,354 | 1,207,768 | 26,911 | 33.3 K to 26.9 K (-19.10 %) |
Mar 12 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Buy | M | 59.52 | 150 | 8,928 | 33,265 | 33.1 K to 33.3 K (+0.45 %) |
Mar 12 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Buy | M | 33.87 | 5,850 | 198,140 | 33,115 | 27.3 K to 33.1 K (+21.46 %) |
Mar 12 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Buy | M | 33.05 | 2,000 | 66,100 | 27,265 | 25.3 K to 27.3 K (+7.92 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 185.22 | 1,633 | 302,464 | 221,864 | 223.5 K to 221.9 K (-0.73 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 185.91 | 4,746 | 882,329 | 223,497 | 228.2 K to 223.5 K (-2.08 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 186.90 | 4,271 | 798,250 | 228,243 | 232.5 K to 228.2 K (-1.84 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 187.48 | 595 | 111,551 | 232,514 | 233.1 K to 232.5 K (-0.26 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 193.45 | 6,193 | 1,198,036 | 233,109 | 239.3 K to 233.1 K (-2.59 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 194.43 | 2,125 | 413,164 | 239,302 | 241.4 K to 239.3 K (-0.88 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 195.54 | 1,082 | 211,574 | 241,427 | 242.5 K to 241.4 K (-0.45 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 196.44 | 461 | 90,559 | 242,509 | 243 K to 242.5 K (-0.19 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 197.94 | 794 | 157,164 | 242,970 | 243.8 K to 243 K (-0.33 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 189.75 | 600 | 113,850 | 32,363 | 33 K to 32.4 K (-1.82 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 190.45 | 603 | 114,841 | 32,963 | 33.6 K to 33 K (-1.80 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 191.43 | 500 | 95,715 | 33,566 | 34.1 K to 33.6 K (-1.47 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 192.54 | 900 | 173,286 | 34,066 | 35 K to 34.1 K (-2.57 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 193.72 | 242 | 46,880 | 34,966 | 35.2 K to 35 K (-0.69 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 196.30 | 500 | 98,150 | 35,208 | 35.7 K to 35.2 K (-1.40 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 197.86 | 200 | 39,572 | 35,708 | 35.9 K to 35.7 K (-0.56 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 190.06 | 700 | 133,042 | 25,265 | 26 K to 25.3 K (-2.70 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 191.20 | 600 | 114,720 | 25,965 | 26.6 K to 26 K (-2.26 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 192.24 | 350 | 67,284 | 26,565 | 26.9 K to 26.6 K (-1.30 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 194.30 | 25 | 4,858 | 26,915 | 26.9 K to 26.9 K (-0.09 %) |
Mar 08 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 196.23 | 400 | 78,492 | 26,940 | 27.3 K to 26.9 K (-1.46 %) |
Mar 04 2021 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Option Exercise | M | 26.12 | 1,000 | 26,120 | 0 | |
Mar 04 2021 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Sell | S | 205.00 | 1,000 | 205,000 | 1,464 | 2.5 K to 1.5 K (-40.58 %) |
Mar 04 2021 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Buy | M | 26.12 | 1,000 | 26,120 | 2,464 | 1.5 K to 2.5 K (+68.31 %) |
Feb 26 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Option Exercise | A | 215.58 | 2,910 | 627,338 | 2,910 | |
Feb 26 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Grant | A | 0.00 | 2,410 | 0 | 35,908 | 33.5 K to 35.9 K (+7.19 %) |
Feb 26 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Option Exercise | A | 215.58 | 2,035 | 438,705 | 2,035 | |
Feb 26 2021 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Grant | A | 0.00 | 1,686 | 0 | 27,340 | 25.7 K to 27.3 K (+6.57 %) |
Feb 26 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Option Exercise | A | 215.58 | 12,601 | 2,716,524 | 12,601 | |
Feb 26 2021 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Grant | A | 0.00 | 10,437 | 0 | 243,764 | 233.3 K to 243.8 K (+4.47 %) |
Jan 26 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Option Exercise | M | 33.87 | 4,000 | 135,480 | 6,887 | |
Jan 26 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Buy | M | 33.87 | 4,000 | 135,480 | 33,498 | 29.5 K to 33.5 K (+13.56 %) |
Jan 06 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 195.77 | 59 | 11,550 | 29,498 | 29.6 K to 29.5 K (-0.20 %) |
Jan 06 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 195.16 | 571 | 111,436 | 29,557 | 30.1 K to 29.6 K (-1.90 %) |
Jan 06 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 193.88 | 218 | 42,266 | 30,128 | 30.3 K to 30.1 K (-0.72 %) |
Jan 06 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 192.74 | 918 | 176,935 | 30,346 | 31.3 K to 30.3 K (-2.94 %) |
Jan 06 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 190.50 | 202 | 38,481 | 31,264 | 31.5 K to 31.3 K (-0.64 %) |
Jan 06 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 190.09 | 1,333 | 253,390 | 31,466 | 32.8 K to 31.5 K (-4.06 %) |
Jan 06 2021 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 188.69 | 656 | 123,781 | 32,799 | 33.5 K to 32.8 K (-1.96 %) |
Dec 18 2020 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 186.18 | 435 | 80,988 | 25,654 | 26.1 K to 25.7 K (-1.67 %) |
Nov 23 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Option Exercise | M | 26.05 | 20,000 | 521,000 | 0 | |
Nov 23 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 187.60 | 1,430 | 268,268 | 233,327 | 234.8 K to 233.3 K (-0.61 %) |
Nov 23 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 186.50 | 6,300 | 1,174,950 | 234,757 | 241.1 K to 234.8 K (-2.61 %) |
Nov 23 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 185.67 | 6,823 | 1,266,826 | 241,057 | 247.9 K to 241.1 K (-2.75 %) |
Nov 23 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 184.69 | 5,447 | 1,006,006 | 247,880 | 253.3 K to 247.9 K (-2.15 %) |
Nov 23 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Buy | M | 26.05 | 20,000 | 521,000 | 253,327 | 233.3 K to 253.3 K (+8.57 %) |
Nov 13 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Option Exercise | M | 38.76 | 934 | 36,202 | 1,000 | |
Nov 13 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Sell | S | 187.73 | 934 | 175,340 | 1,464 | 2.4 K to 1.5 K (-38.95 %) |
Nov 13 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Option Exercise | M | 38.76 | 934 | 36,202 | 1,000 | |
Nov 13 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Buy | M | 38.76 | 934 | 36,202 | 2,398 | 1.5 K to 2.4 K (+63.80 %) |
Nov 13 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Sell | S | 187.73 | 934 | 175,340 | 1,464 | 2.4 K to 1.5 K (-38.95 %) |
Nov 13 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Buy | M | 38.76 | 934 | 36,202 | 2,398 | 1.5 K to 2.4 K (+63.80 %) |
Sep 14 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Option Exercise | M | 26.05 | 45,351 | 1,181,394 | 20,000 | |
Sep 14 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 149.30 | 2,397 | 357,872 | 233,327 | 235.7 K to 233.3 K (-1.02 %) |
Sep 14 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 148.56 | 26,966 | 4,006,069 | 235,724 | 262.7 K to 235.7 K (-10.27 %) |
Sep 14 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 147.68 | 11,132 | 1,643,974 | 262,690 | 273.8 K to 262.7 K (-4.07 %) |
Sep 14 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 146.85 | 4,856 | 713,104 | 273,822 | 278.7 K to 273.8 K (-1.74 %) |
Sep 14 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Buy | M | 26.05 | 45,351 | 1,181,394 | 278,678 | 233.3 K to 278.7 K (+19.44 %) |
Aug 10 2020 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Option Exercise | M | 33.87 | 5,000 | 169,350 | 5,850 | |
Aug 10 2020 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 153.79 | 5,000 | 768,950 | 26,089 | 31.1 K to 26.1 K (-16.08 %) |
Aug 10 2020 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Buy | M | 33.87 | 5,000 | 169,350 | 31,089 | 26.1 K to 31.1 K (+19.17 %) |
Aug 04 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Option Exercise | A | 67.71 | 2,109 | 142,800 | 0 | |
Aug 04 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Sell | S | 151.77 | 986 | 149,645 | 1,464 | 2.5 K to 1.5 K (-40.24 %) |
Aug 04 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Sell | S | 151.96 | 2,109 | 320,484 | 2,450 | 4.6 K to 2.5 K (-46.26 %) |
Aug 04 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Buy | M | 67.71 | 2,109 | 142,800 | 4,559 | 2.5 K to 4.6 K (+86.08 %) |
Jun 22 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 116.56 | 2,568 | 299,326 | 100,734 | 103.3 K to 100.7 K (-2.49 %) |
Jun 22 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 115.76 | 8,217 | 951,200 | 103,302 | 111.5 K to 103.3 K (-7.37 %) |
Jun 22 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 114.49 | 5,243 | 600,271 | 111,519 | 116.8 K to 111.5 K (-4.49 %) |
Jun 22 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 113.58 | 2,677 | 304,054 | 116,762 | 119.4 K to 116.8 K (-2.24 %) |
Jun 15 2020 | RGEN | REPLIGEN CORP | EGLINTON MANNER CARRIE | Director | Option Exercise | A | 113.78 | 2,794 | 317,901 | 2,794 | |
May 26 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Option Exercise | M | 32.40 | 3,086 | 99,986 | 50,154 | |
May 26 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Option Exercise | M | 24.98 | 39,037 | 975,144 | 0 | |
May 26 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Option Exercise | M | 16.55 | 7,916 | 131,010 | 1 | |
May 26 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Buy | M | 32.40 | 3,086 | 99,986 | 233,327 | 230.2 K to 233.3 K (+1.34 %) |
May 26 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 141.58 | 100 | 14,158 | 230,241 | 230.3 K to 230.2 K (-0.04 %) |
May 26 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 140.99 | 1,377 | 194,143 | 230,341 | 231.7 K to 230.3 K (-0.59 %) |
May 26 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 140.04 | 28,980 | 4,058,359 | 231,718 | 260.7 K to 231.7 K (-11.12 %) |
May 26 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Sell | S | 139.17 | 16,496 | 2,295,748 | 260,698 | 277.2 K to 260.7 K (-5.95 %) |
May 26 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Buy | M | 24.98 | 39,037 | 975,144 | 277,194 | 238.2 K to 277.2 K (+16.39 %) |
May 26 2020 | RGEN | REPLIGEN CORP | Hunt Anthony | Chief Executive Off ... | Buy | M | 16.55 | 7,916 | 131,010 | 238,157 | 230.2 K to 238.2 K (+3.44 %) |
May 26 2020 | RGEN | REPLIGEN CORP | BARTHELEMY NICOLAS | Director | Option Exercise | M | 67.71 | 2,109 | 142,800 | 0 | |
May 26 2020 | RGEN | REPLIGEN CORP | BARTHELEMY NICOLAS | Director | Sell | S | 142.53 | 3,009 | 428,873 | 2,664 | 5.7 K to 2.7 K (-53.04 %) |
May 26 2020 | RGEN | REPLIGEN CORP | BARTHELEMY NICOLAS | Director | Buy | M | 67.71 | 2,109 | 142,800 | 5,673 | 3.6 K to 5.7 K (+59.18 %) |
May 21 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 140.29 | 182 | 25,533 | 119,439 | 119.6 K to 119.4 K (-0.15 %) |
May 21 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 139.40 | 282 | 39,311 | 119,621 | 119.9 K to 119.6 K (-0.24 %) |
May 21 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 136.98 | 43 | 5,890 | 119,903 | 119.9 K to 119.9 K (-0.04 %) |
May 21 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 135.91 | 10 | 1,359 | 119,946 | 120 K to 119.9 K (-0.01 %) |
May 21 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 140.29 | 182 | 25,533 | 119,439 | 119.6 K to 119.4 K (-0.15 %) |
May 21 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 139.40 | 282 | 39,311 | 119,621 | 119.9 K to 119.6 K (-0.24 %) |
May 21 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 136.98 | 43 | 5,890 | 119,903 | 119.9 K to 119.9 K (-0.04 %) |
May 21 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 135.91 | 10 | 1,359 | 119,946 | 120 K to 119.9 K (-0.01 %) |
May 19 2020 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 140.69 | 435 | 61,200 | 26,089 | 26.5 K to 26.1 K (-1.64 %) |
May 19 2020 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 140.43 | 660 | 92,684 | 32,267 | 32.9 K to 32.3 K (-2.00 %) |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Option Exercise | A | 128.18 | 1,761 | 225,725 | 1,761 | |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 142.45 | 80 | 11,396 | 119,956 | 120 K to 120 K (-0.07 %) |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 141.45 | 77 | 10,892 | 120,036 | 120.1 K to 120 K (-0.06 %) |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 140.62 | 180 | 25,312 | 120,113 | 120.3 K to 120.1 K (-0.15 %) |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 139.32 | 122 | 16,997 | 120,293 | 120.4 K to 120.3 K (-0.10 %) |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 138.60 | 269 | 37,283 | 120,415 | 120.7 K to 120.4 K (-0.22 %) |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 136.92 | 160 | 21,907 | 120,684 | 120.8 K to 120.7 K (-0.13 %) |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Sell | S | 135.76 | 712 | 96,661 | 120,844 | 121.6 K to 120.8 K (-0.59 %) |
May 19 2020 | RGEN | REPLIGEN CORP | DAWES KAREN A | Director | Grant | A | 0.00 | 722 | 0 | 121,556 | 120.8 K to 121.6 K (+0.60 %) |
May 19 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Option Exercise | A | 128.18 | 1,285 | 164,711 | 1,285 | |
May 19 2020 | RGEN | REPLIGEN CORP | RYAN THOMAS F JR | Director | Grant | A | 0.00 | 527 | 0 | 2,450 | 1.9 K to 2.5 K (+27.41 %) |
May 19 2020 | RGEN | REPLIGEN CORP | BARTHELEMY NICOLAS | Director | Option Exercise | A | 128.18 | 1,285 | 164,711 | 1,285 | |
May 19 2020 | RGEN | REPLIGEN CORP | BARTHELEMY NICOLAS | Director | Grant | A | 0.00 | 527 | 0 | 3,564 | 3 K to 3.6 K (+17.35 %) |
May 19 2020 | RGEN | REPLIGEN CORP | MUIR GLENN P | Director | Option Exercise | A | 128.18 | 1,285 | 164,711 | 1,285 | |
May 19 2020 | RGEN | REPLIGEN CORP | MUIR GLENN P | Director | Grant | A | 0.00 | 527 | 0 | 5,905 | 5.4 K to 5.9 K (+9.80 %) |
May 15 2020 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Option Exercise | M | 32.40 | 9,024 | 292,378 | 3,086 | |
May 15 2020 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Option Exercise | M | 26.05 | 3,170 | 82,579 | 0 | |
May 15 2020 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 132.37 | 846 | 111,985 | 32,927 | 33.8 K to 32.9 K (-2.50 %) |
May 15 2020 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 131.38 | 3,013 | 395,848 | 33,773 | 36.8 K to 33.8 K (-8.19 %) |
May 15 2020 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 130.20 | 1,700 | 221,340 | 36,786 | 38.5 K to 36.8 K (-4.42 %) |
May 15 2020 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 128.70 | 1,612 | 207,464 | 38,486 | 40.1 K to 38.5 K (-4.02 %) |
May 15 2020 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 127.75 | 2,865 | 366,004 | 40,098 | 43 K to 40.1 K (-6.67 %) |
May 15 2020 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Sell | S | 126.77 | 5,358 | 679,234 | 42,963 | 48.3 K to 43 K (-11.09 %) |
May 15 2020 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Buy | M | 32.40 | 9,024 | 292,378 | 48,321 | 39.3 K to 48.3 K (+22.96 %) |
May 15 2020 | RGEN | REPLIGEN CORP | Snodgres Jon | Chief Financial Off ... | Buy | M | 26.05 | 3,170 | 82,579 | 39,297 | 36.1 K to 39.3 K (+8.77 %) |
May 15 2020 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Option Exercise | M | 33.87 | 2,000 | 67,740 | 10,850 | |
May 15 2020 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Option Exercise | M | 33.05 | 6,000 | 198,300 | 4,000 | |
May 15 2020 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 128.55 | 95 | 12,212 | 26,524 | 26.6 K to 26.5 K (-0.36 %) |
May 15 2020 | RGEN | REPLIGEN CORP | KURIYEL RALF | Senior VP, R&D | Sell | S | 128.02 | 6,293 | 805,630 | 26,619 | 32.9 K to 26.6 K (-19.12 %) |